Document:

JAZZ Q2 2015 EX 10.2

JAZZ PHARMACEUTICALS PLC
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
Non-employee members of the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”).  The cash compensation and equity grants described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) who may be eligible to receive such cash compensation or equity grants, unless such Non-Employee Director declines the receipt of such cash compensation or equity grants by written notice to the Company.  This Policy shall remain in effect until it is revised or rescinded by further action of the Board. 
1.     Cash Compensation.
(a)    Subject to Section 1(b) below, each Non-Employee Director shall be eligible to receive an annual retainer of $55,000 for service on the Board.  In addition, a Non-Employee Director serving as:
		
	i.
	lead independent director of the Board shall be eligible to receive an additional annual retainer of $25,000 for such service;

		
	ii.
	chairperson of the Audit Committee shall be eligible to receive an additional annual retainer of $25,000 for such service;

		
	iii.
	members (other than the chairperson) of the Audit Committee shall be eligible to receive an additional annual retainer of $15,000 for such service;

		
	iv.
	chairperson of the Compensation Committee shall be eligible to receive an additional annual retainer of $22,500 for such service;

		
	v.
	members (other than the chairperson) of the Compensation Committee shall be eligible to receive an additional annual retainer of $12,500 for such service;

		
	vi.
	chairperson of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $20,000 for such service; 

		
	vii.
	members (other than the chairperson) of the Nominating and Corporate Governance Committee shall be eligible to receive an additional annual retainer of $10,000 for such service;

		
	viii.
	chairperson of the Transaction Committee shall be eligible to receive an additional annual retainer of $22,500 for such service; and

 
 
 
 
829735 v12/SD 

		
	ix.
	members (other than the chairperson) of the Transaction Committee shall be eligible to receive an additional annual retainer of $12,500 for such service.

The annual retainers shall be paid in four equal quarterly installments, earned upon the completion of service in each calendar quarter. 
(b)    Each person who is elected or appointed to be a Non-Employee Director or who is appointed to serve as lead independent director or a member or chairperson of one of the Committees described above, in each case other than on the first day of a calendar quarter, shall be eligible to receive a pro rata amount of the annual retainers described above with respect to the calendar quarter in which such person becomes a Non-Employee Director, lead independent director or a member or chairperson of one of the Committees, as applicable, which pro rata amount reflects a reduction for each day during the calendar quarter prior to the date of such election or appointment.
(c)    Each Non-Employee Director will be entitled to reimbursement from the Company for his or her reasonable travel (including airfare and ground transportation), lodging and meal expenses incidental to meetings of the Board or committees thereof.  If any Reimbursement Payment is subject to tax imposed by the Irish Revenue Commissioners (“Revenue”), each Non-Employee Director will be entitled to a payment, up to an amount (“Gross-Up Payment”) such that after the deduction of all taxes (including, without limitation, any income taxes calculated at the rate applicable to each Non-Employee Director for the year in which the expenses were incurred) on the Gross-Up Payment, the Non-Employee Director will retain an amount equal to the full Reimbursement Payment.  All taxes due will be paid by the Company to Revenue.
2.     Equity Compensation.  The stock options described below shall be granted under and shall be subject to the terms and provisions of the Company’s Amended and Restated 2007 Non-Employee Directors Stock Option Plan (the “NEDSOP”), unless the Board determines that such stock options shall be granted under and subject to the terms and provisions of the Company’s 2007 Equity Incentive Plan (the “2007 Plan”).  The restricted stock unit (“RSU”) awards described below shall be granted under and shall be subject to the terms and provisions of the 2007 Plan.
(a)     Initial Grants.  A person who is elected or appointed to be a Non-Employee Director for the first time on or following 30 April 2015 automatically shall be granted a nonstatutory stock option to purchase 5,695 ordinary shares of the Company (an “Initial Option Grant”) and an RSU award for 2,185 RSUs (an “Initial RSU Grant”) on the second trading day following the filing date of the Company’s next quarterly or annual report filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that occurs after the date of such initial election or appointment.  The Initial Option Grant and Initial RSU Grant shall collectively be referred to as an “Initial Grant.”
(b)     Continuing Grants.  Subject to Section 2(c) below, a person who is a Non-Employee Director on or following 30 April 2015 automatically shall be granted a nonstatutory

2
 
 
 
 
829735 v12/SD 

stock option to purchase 3,415 ordinary shares of the Company (a “Continuing Option Grant”) and an RSU award for 1,310 RSUs (a “Continuing RSU Grant”) on the second trading day following the filing date of the Company’s next quarterly or annual report filed under the Exchange Act that occurs after the date of each annual general meeting of the Company’s shareholders.  The Continuing Option Grant and Continuing RSU Grant shall collectively be referred to as a “Continuing Grant.”  Notwithstanding the foregoing, each person who is elected or appointed to be a Non-Employee Director for the first time at an annual general meeting of the Company’s shareholders shall not be granted a Continuing Grant with respect to such meeting.
(c)     Continuing Grants for Certain New Non-Employee Directors.  If a person is elected or appointed to be a Non-Employee Director for the first time other than at an annual general meeting of the Company’s shareholders, such Non-Employee Director automatically shall be granted a Continuing Grant with respect to the next annual general meeting in accordance with Section 2(b) above, provided that the date of such initial election or appointment is not less than four calendar months prior to the date of the next annual general meeting.  If the date of such initial election or appointment is less than four calendar months prior to the date of the next annual general meeting, such Non-Employee Director shall not be granted a Continuing Grant under Section 2(b) above with respect to such next annual general meeting.
 (d)     Terms of Options Granted to Non-Employee Directors.
(i)    Terms and Conditions.  The terms and conditions applicable to each Initial Option Grant and Continuing Option Grant granted to Non-Employee Directors pursuant to this Policy shall be subject to the terms and conditions in the forms of stock option notice of grant and option award agreement previously approved by the Board or the Compensation Committee and the NEDSOP or the 2007 Plan, in each case, as applicable.
(ii)     Vesting. 
(a)     Each Initial Option Grant granted to a Non-Employee Director shall vest and become exercisable as to 1/3 of the shares subject to such option on the first anniversary of the date such Non-Employee Director is first elected or appointed to the Board (the “Initial Grant Vesting Commencement Date”) and as to the remainder of the shares, in 24 equal monthly installments thereafter, subject to the Non-Employee Director’s Continuous Service (as defined in the NEDSOP or the 2007 Plan, as applicable) through such dates. 
(b)    Each Continuing Option Grant granted to a Non-Employee Director shall vest and become exercisable in 12 equal monthly installments of 1/12 of the shares subject to such option on the first day of each calendar month following the date of the annual general meeting of the Company’s shareholders in such year (the “Continuing Grant Vesting Commencement Date”), subject to the Non-Employee Director’s Continuous Service (as defined in the NEDSOP or the 2007 Plan, as applicable) through such dates. 

3
 
 
 
 
829735 v12/SD 

(c)     Notwithstanding the vesting provisions in clauses (a) and (b) hereof, if a Non-Employee Director does not stand for reelection at an annual general meeting of the Company’s shareholders in the year in which his or her term expires or otherwise resigns effective at an annual general meeting of the Company’s shareholders and, in either case, the Non-Employee Director’s Continuous Service terminates at such annual general meeting, then effective as of the date of such annual general meeting:
(1)    the unvested portion, if any, of an Initial Option Grant granted to such Non-Employee Director shall become vested and exercisable with respect to the portion of the Initial Option Grant that would have vested through the anniversary of the Initial Grant Vesting Commencement Date in the year of such annual general meeting; and 
(2)    the unvested portion, if any, of a Continuing Option Grant granted to such Non-Employee Director shall become vested and exercisable in full. 
(e)     Terms of RSUs Granted to Non-Employee Directors.
(i)     Terms and Conditions.  The terms and conditions applicable to each Initial RSU Grant and Continuing RSU Grant granted to Non-Employee Directors pursuant to this Policy shall be subject to the terms and conditions in the forms of RSU notice of grant and RSU award agreement previously approved by the Board or the Compensation Committee, as applicable, and the 2007 Plan.
(ii)     Vesting. 
(a)     Each Initial RSU Grant granted to a Non-Employee Director shall vest in three equal annual installments on each of the first three anniversaries of the Initial Grant Vesting Commencement Date, subject to the Non-Employee Director’s Continuous Service (as defined in the 2007 Plan) through such dates. 
(b)    Each Continuing RSU Grant granted to a Non-Employee Director shall vest in full on the first anniversary of the Continuing Grant Vesting Commencement Date, subject to the Non-Employee Director’s Continuous Service (as defined in the 2007 Plan) through such date.
(c)     Notwithstanding the vesting provisions in clauses (a) and (b) hereof, if a Non-Employee Director does not stand for reelection at an annual general meeting of the Company’s shareholders in the year in which his or her term expires or otherwise resigns effective at an annual general meeting of the Company’s shareholders and, in either case, the Non-Employee Director’s Continuous Service terminates at such annual general meeting, then effective as of the date of such annual general meeting:
(1)    the unvested portion, if any, of an Initial RSU Grant granted to such Non-Employee Director shall become vested with respect to the 

4
 
 
 
 
829735 v12/SD 

portion of the Initial RSU Grant that would have vested on the anniversary of the Initial Grant Vesting Commencement Date in the year of such annual general meeting; and
(2)    the unvested portion, if any, of a Continuing RSU Grant granted to such Non-Employee Director shall become vested in full.
 
*****
Adopted by the Board of Directors of Jazz Pharmaceuticals plc on 2 May 2013.
Amended and restated by the Board of Directors of Jazz Pharmaceuticals plc on 1 August 2013.
Amended and restated by the Board of Directors of Jazz Pharmaceuticals plc on 1 May 2014.
Amended and restated by the Board of Directors of Jazz Pharmaceuticals plc on 30 October 2014.
Amended and restated by the Board of Directors of Jazz Pharmaceuticals plc on 30 April 2015.

5
 
 
 
 
829735 v12/SDJAZZ Q2 2015 EX 10.3

DATED  MAY 13,  2015
    

	
	
	

NOVATION AGREEMENT
relating to
Royalty Bearing Licence Agreement and Supply Agreement re Erwinia-Derived Asparaginase

1

THIS NOVATION AGREEMENT is dated May 13, 2015
BETWEEN:
		
	(1)
	EUSA PHARMA SAS whose registered address is Les Jardins D'Ecole, allee des sequoias F69760, Limonest, France ("EUSA");

		
	 (2)
	THE SECRETARY OF STATE FOR HEALTH acting through PUBLIC HEALTH ENGLAND with offices at Porton Down, Salisbury, Wiltshire SP4 0JG (“PHE"); and

		
	(3)
	PORTON BIOPHARMA LIMITED (Company Number 9331560) having its registered office at Manor Farm Road, Porton, Salisbury, Wiltshire SP4 0JG (“PBL”). 

WHEREAS:
		
	(A)
	This Novation Agreement is supplemental to a Contract made between OPi SA and the Health Protection Agency having the title "Royalty Bearing Licence Agreement and Supply Agreement re Erwinia-Derived Asparaginase" dated 22 July 2005 ("Contract").

		
	(B)
	OPi SA subsequently changed its name to EUSA Pharma SAS.

		
	(C)
	On 1 April 2013, the HPA became part of Public Health England, a new executive agency of the Department of Health. PHE is thus now the party to the Contract in place of HPA.  

		
	(D)
	The business, assets, resources and staff of PHE utilised in the performance of its obligations under the Contract are being transferred to PBL and upon completion on April 1, 2015  (the "Effective Date"), for the purposes of the Contract, PBL has taken over the rights and obligations of HPA/PHE in respect of the Contract.

		
	(E)
	PHE wishes to be released and discharged from the Contract and EUSA agrees to release and discharge PHE upon the terms of this Novation Agreement. 

IT IS AGREED as follows:
		
	1.
	NOVATION

		
	1.1
	On and with effect from the Effective Date, subject to Clause 2 and in consideration of each party accepting the obligations herein:

		
	1.1.1
	PBL assumes all and any of the obligations and liabilities whatsoever of PHE to EUSA , and shall be assigned any and all of the rights whatsoever, under or arising from the Contract in every way as if PBL is a party to the Contract in place of PHE.

		
	1.1.2
	EUSA releases and discharges PHE from all and any of its obligations and liabilities whatsoever to EUSA under or arising from the Contract.

		
	1.1.3
	EUSA is and shall be bound, for the benefit of PBL, by all of its obligations and liabilities under or arising from the Contract (to the extent that such obligations and/or liabilities have not been fully and properly discharged prior to the Effective Date) in every way as if PBL had originally been a party to the Contract in place of PHE.

		
	1.1.4
	PBL is and shall be bound, for the benefit of EUSA, by all of its obligations and liabilities under or arising from the Contract (to the extent that such obligations and/or liabilities have not been fully and properly discharged prior to the Effective Date) in every way as if PBL had originally been a party to the Contract in place of PHE.

		
	1.1.5
	PHE releases and discharges EUSA from all and any of its obligations and liabilities whatsoever to PHE under or arising from the Contract.

2

		
	2.
	OUTSTANDING OBLIGATIONS AT THE EFFECTIVE DATE

		
	2.1
	The parties to this Novation Agreement acknowledge and agree that:

		
	2.1.1
	any obligations of EUSA pursuant to the terms of the Contract which remained undischarged at the Effective Date shall not be deemed to be waived by PBL by virtue of the novation of the Contract pursuant to the terms of this Novation Agreement, but shall be performed by EUSA in accordance with Clause 1.1.3.

		
	2.1.2
	any obligations of PHE pursuant to the terms of the Contract which remained undischarged at the Effective Date shall not be deemed to be waived by EUSA by virtue of the novation of the Contract pursuant to the terms of this Novation Agreement, but shall be performed by PBL in accordance with Clause 1.1.4.

		
	2.2
	Nothing in this Novation Agreement shall affect or prejudice any obligation, claim or demand whatsoever which either PHE or EUSA may have against each other relating to matters arising prior to the Effective Date.

		
	3.
	COUNTERPARTS

This Novation Agreement may be executed in any number of counterparts and by each of the parties on separate counterparts each of which when executed and delivered shall be deemed to be an original, but all the counterparts together shall constitute one and the same agreement.
		
	4.
	VARIATION

A variation of this Novation Agreement is valid only if it is in writing and signed by the parties or their duly authorised representative.
		
	5.
	THIRD PARTY RIGHTS

A person who is not a Party to this Novation Agreement has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce this Novation Agreement.
		
	6.
	GOVERNING LAW

This Novation Agreement, the jurisdiction clause contained in it and all non-contractual obligations arising in any way whatsoever out of or in connection with this Novation Agreement are governed by, construed and take effect in accordance with the law of England and Wales.

(Remainder of page intentionally left blank.)

3

		
	7.
	JURISDICTION

The courts of England and Wales have exclusive jurisdiction to settle any claim, dispute or matter of difference which may arise in any way whatsoever out of or in connection with this Novation Agreement (including without limitation claims for set‐off or counterclaim) or the legal relationships established by this Novation Agreement.
EXECUTED AS A DEED by or on behalf of the parties on the date which first appears in this Novation Agreement

	
		
	EXECUTED AS A DEED by a duly authorised representative    for and on behalf of EUSA PHARMA SAS a company incorporated in France by Iain McGill, being a person who is, in accordance with the laws of that territory, acting under the authority of the company.
	

/s/ Iain McGill

	EXECUTED AS A DEED by  a duly authorised representative for and on behalf of  THE SECRETARY OF STATE FOR HEALTH acting through PUBLIC HEALTH ENGLAND in the presence of
_Rebecca Wilson_____________________, a duly authorised representative   

	

/s/ Michael Brodie

/s/ Rebecca Wilson
[Address]

	EXECUTED AS A DEED by PORTON BIOPHARMA LIMITED acting by
_____________________________, a director and ______________________________, a director/its secretary OR in the presence of _____________________________
 

Rebecca Wilson

	

/s/ Roger Hinton

AND

/s/ Rebecca Wilson

If signed by a witness, the name, address and occupation of such witness:  

Rebecca Wilson
[Address]
Consultant

4

	
			
	 
	 
	 

	As a partial sublicensee of EUSA Pharma SAS under the Contract, Jazz Pharmaceuticals Ireland Limited hereby acknowledges the Novation Agreement.

JAZZ PHARMACEUTICALS IRELAND LIMITED

By:  /s/ Paul Treacy
Name   Paul Treacy
Title:  Director

	 
	 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]